4//SEC Filing
Celator Pharmaceuticals Inc 4
Accession 0000919574-15-004911
CIK 0001327467operating
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 1:39 PM ET
Size
12.1 KB
Accession
0000919574-15-004911
Insider Transaction Report
Form 4
Morenstein Scott D
Director
Transactions
- Award
Stock Option (Right to Buy)
2015-06-11+14,000→ 14,000 totalExercise: $2.60Exp: 2025-06-11→ Common Stock (14,000 underlying)
Holdings
- 358
Warrant
Exercise: $3.58Exp: 2020-04-29→ Common Stock (358 underlying) - 314,611(indirect: See Footnote)
Warrant
Exercise: $3.58Exp: 2020-04-29→ Common Stock (314,611 underlying) - 14,000
Stock Option (Right to Buy)
Exercise: $2.80Exp: 2024-06-12→ Common Stock (14,000 underlying) - 28,000
Stock Option (Right to Buy)
Exercise: $3.12Exp: 2023-06-03→ Common Stock (28,000 underlying)
Footnotes (6)
- [F1]The options vest as follows: (i) 4,667 options vest on June 10, 2016; (ii) 1,167 options vest on the 11th day of each of seven consecutive fiscal quarters beginning on September 11, 2016 and continuing through March 11, 2018, and (iii) 1,164 options vest on June 11, 2018.
- [F2]The options vest as follows: (i) 4,666 options vested on June 12, 2015 and are currently exercisable (ii) 1,166 options vest on the 12th day of each of seven consecutive fiscal quarters beginning on September 12, 2015 and continuing through March 12, 2017; and (iii) 1,172 options vest on June 12, 2017.
- [F3]These securities are owned by Scott D. Morenstein, who is the Reporting Person.
- [F4]The options vest as follows: (i) 9,334 options vested on June 3, 2014 and are currently exercisable; (ii) 9,332 vested over four consecutive fiscal quarters beginning on September 3, 2014 through June 3, 2015 and are currently exercisable, (iii) 2,333 options vest on the third day of each of three consecutive fiscal quarters beginning on September 3, 2015 and continuing through March 3, 2016; and (iv) 2,335 options vest on June 3, 2016.
- [F5]These warrants are currently exercisable.
- [F6]The reported securities are directly owned by Valence CDK SPV, L.P. ("CDK SPV"). Valence Life Sciences GP II, LLC ("GP II") is the sole general partner of CDK SPV. In his capacity as an advisor to GP II, the reporting person may be deemed to beneficially own securities held by CDK SPV. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Documents
Issuer
Celator Pharmaceuticals Inc
CIK 0001327467
Entity typeoperating
Related Parties
1- filerCIK 0001327467
Filing Metadata
- Form type
- 4
- Filed
- Jun 14, 8:00 PM ET
- Accepted
- Jun 15, 1:39 PM ET
- Size
- 12.1 KB